{"id":"NCT04264819","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration","officialTitle":"A One-year, Single-arm, Open-label, Multicenter Study Assessing the Effect of Brolucizumab on Disease Control in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (SWIFT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-14","primaryCompletion":"2022-10-05","completion":"2023-05-10","firstPosted":"2020-02-11","resultsPosted":"2024-11-07","lastUpdate":"2024-11-07"},"enrollment":295,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-Related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"RTH258/Brolucizumab","otherNames":[]}],"arms":[{"label":"RTH258/Brolucizumab","type":"EXPERIMENTAL"}],"summary":"Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid exudation, and fibrosis, resulting in photoreceptor damage and vision loss.","primaryOutcome":{"measure":"Number of Patients With no Disease Activity at Week 16 in the Study Eye","timeFrame":"Week 16","effectByArm":[{"arm":"RTH258/Brolucizumab","deltaMin":89,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":51,"countries":["France"]},"refs":{"pmids":["37343623"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":295},"commonTop":["Vitreous floaters - Study eye","Neovascular age-related macular degeneration - Fellow eye","Hypertension","Ocular hypertension - Study eye","Vitreous detachment - Study eye"]}}